^

Opinion

Garenoxacin shows promise for community-acquired pneumonia

YOUR DOSE OF MEDICINE - Charles C. Chante MD -

An experimental fluoroquinole compared favorably with amoxicillin or ceftriaxone for treating community-acquired pneumonia in two phase III trials, researchers reported in poster presentations at the annual Inter-science Conference on Antimicrobial Agents and Chemotherapy. One study of 308 outpatients in Europe and Russia with mild to moderate community-acquired pneumonia (CAP) showed similar response rates in patients given 5 days of oral garenoxacin or 10 days of oral amoxicillin.

The company is developing garenoxacin and the lead investigator in the study was of Ege University, Izmir, Turkey. Evaluations 7-14 days after completing therapy showed clinical responses in 91% of patients randomized to once-daily doses of 400 mg garenoxacin and in 87% of patients given amoxicillin 1 g t.i.d.

Bacterial eradication was achieved in 88% of the garenoxacin group and 91% of the amoxicillin group. Drug-related adverse events — most commonly diarrhea, headache, abdominal pain, and nausea — were seen in 13% of patients in the garenoxacin group and 12% of those in the amoxicillin group.

The second study of 406 hospitalized patients with CAP showed an 88% clinical cure rate in 328 evaluable patients regardless of treatment group. Patients were randomized to either IV garenoxacin 400 mg/day with possible step-down to oral carithromycin 500 mg b.i.d. If atypical pneumonia was suspected, the ceftriaxone patients also could receive IV erythromycin 0.5-1 g every 6 hours. Patients were treated for 7-14 days and evaluated for cure 7-14 days after completing therapy.

vuukle comment

AMOXICILLIN

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DAYS

GARENOXACIN

GROUP

IZMIR

PATIENTS

PLACE

  • Latest
  • Trending
Latest
Latest
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with